Binding of orthosteric ligands to the allosteric site of the M2 muscarinic cholinergic receptor

被引:28
|
作者
Redka, Dar'ya S. [1 ]
Pisterzi, Luca F. [1 ]
Wells, James W. [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
D O I
10.1124/mol.108.048074
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The M(2) muscarinic receptor has two topographically distinct sites: the orthosteric site and an allosteric site recognized by compounds such as gallamine. It also can exhibit cooperative effects in the binding of orthosteric ligands, presumably to the orthosteric sites within an oligomer. Such effects would be difficult to interpret, however, if those ligands also bound to the allosteric site. Monomers of the hemagglutinin (HA)- and FLAG-tagged human M(2) receptor therefore have been purified from coinfected Sf9 cells and examined for any effect of the antagonist N-methyl scopolamine or the agonist oxotremorine-M on the rate at which N-[(3)H] methyl scopolamine dissociates from the orthosteric site (k(obsd)). The predominantly monomeric status was confirmed by coimmunoprecipitation and by cross-linking with bis(sulfosuccinimidyl) suberate. Both N-methyl scopolamine and oxotremorine-M acted in a cooperative manner to decrease k(obsd) by 4.5- and 9.1-fold, respectively; the corresponding estimates of affinity (log K(L)) are -2.55 +/- 0.13 and -2.29 +/- 0.14. Gallamine and the allosteric ligand obidoxime decreased kobsd by more than 100-fold (log K(L) = -4.12 +/- 0.04) and by only 1.1-fold (log K(L) = -1.73 +/- 0.91), respectively. Obidoxime reversed the effect of N-methyl scopolamine, oxotremorine-M, and gallamine in a manner that could be described by a model in which all four ligands compete for a common allosteric site. Ligands generally assumed to be exclusively orthosteric therefore can act at the allosteric site of the M(2) receptor, albeit at comparatively high concentrations.
引用
收藏
页码:834 / 843
页数:10
相关论文
共 50 条
  • [31] Allosteric modulation of muscarinic M2 receptor mediated G protein activation
    Eckstein, N
    Tränkle, C
    Sadée, W
    Mohr, K
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R21 - R21
  • [32] Use of Acetylcholine Mustard to Study Allosteric Interactions at the M2 Muscarinic Receptor
    Suga, Hinako
    Figueroa, Katherine W.
    Ehlert, Frederick J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (02): : 518 - 528
  • [33] Muscarinic receptors:: The allosteric/orthosteric epitope M2 422tryptophan mediates strong negative cooperativity between an allosteric antagonist and acetylcholine
    Prilla, S.
    Antony, J.
    Traenkle, C.
    Mohr, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 : 21 - 21
  • [34] Exploration of the Orthosteric/Allosteric Interface in Human M1 Muscarinic Receptors by Bitopic Fluorescent Ligands
    Daval, Sandrine B.
    Kellenberger, Esther
    Bonnet, Dominique
    Utard, Valerie
    Galzi, Jean-Luc
    Ilien, Brigitte
    MOLECULAR PHARMACOLOGY, 2013, 84 (01) : 71 - 85
  • [35] Atypical muscarinic allosteric modulation:: Cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors
    Tränkle, C
    Dittmann, A
    Schulz, U
    Weyand, O
    Buller, S
    Jöhren, K
    Heller, E
    Birdsall, NJM
    Holzgrabe, U
    Ellis, J
    Höltje, HD
    Mohr, K
    MOLECULAR PHARMACOLOGY, 2005, 68 (06) : 1597 - 1610
  • [36] Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder
    Cannon, D. M.
    Klaver, J. K.
    Gandhi, S. K.
    Solorio, G.
    Peck, S. A.
    Erickson, K.
    Savitz, J.
    Akula, N.
    Eckelman, W. C.
    Furey, M. L.
    Sahakian, B. J.
    McMahon, F. J.
    Drevets, W. C.
    MOLECULAR PSYCHIATRY, 2011, 16 (04) : 407 - 418
  • [37] Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M2 receptors
    Tränkle, C
    Weyand, O
    Schröter, A
    Mohr, K
    MOLECULAR PHARMACOLOGY, 1999, 56 (05) : 962 - 965
  • [38] Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder
    D M Cannon
    J K Klaver
    S K Gandhi
    G Solorio
    S A Peck
    K Erickson
    J Savitz N Akula
    W C Eckelman
    M L Furey
    B J Sahakian
    F J McMahon
    W C Drevets
    Molecular Psychiatry, 2011, 16 : 407 - 418
  • [39] ALLOSTERIC INTERACTIONS AT THE M1, M2 AND M3-MUSCARINIC-RECEPTOR SUBTYPES
    LEE, NH
    ELFAKAHANY, EE
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 256 (02): : 468 - 479
  • [40] Allosteric regulation of the binding of [H-3]acetylcholine to m2 muscarinic receptors
    Gnagey, A
    Ellis, J
    BIOCHEMICAL PHARMACOLOGY, 1996, 52 (11) : 1767 - 1775